What does CUSIP 641288105 represent in this 13F holders report?

CUSIP 641288105 is the security identifier for NPCE - NeuroPace Inc - Common Stock, $0.01 par value used to aggregate holder disclosures.

How many institutions held NPCE - NeuroPace Inc - Common Stock, $0.01 par value in Q1 2024?

53 institutional investors reported NPCE - NeuroPace Inc - Common Stock, $0.01 par value for Q1 2024. Use the holders table for investor-level position and value details.

NeuroPace Inc - Common Stock, $0.01 par value (NPCE)

CUSIP: 641288105

Q1 2024 13F Holders as of 31 Mar 2024

Security type / class: Equity / Common Stock, $0.01 par value
Total 13F shares: 13,364,973
Total 13F value: $176,414,273
Share change: +674,659
Put/Call ratio: 26%
SEC-reported price per share: $13.20
Number of holders: 53
Value change: +$9,053,052
Number of buys: 37
Number of sells: 17
Shares outstanding: 34,317,804

Security key

641288105

Report period

Q1 2024

Institutions

Top holders

NPCE full security history Ownership snapshot Full 13F holder table NeuroPace Inc SEC filings NeuroPace Inc company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of NPCE - NeuroPace Inc - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

ORBIMED ADVISORS LLC

Disclosed value leader

ORBIMED ADVISORS LLC

Comparable rows

15/15

Latest evidence

31 Dec 2023

13F Lead comparable stake: 12% Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 12%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.

Comparable ownership Top 5

ORBIMED ADVISORS LLC 12%

MORGAN STANLEY 7.2%

Soleus Capital Management, L.P. 7.1%

Nantahala Capital Management, LLC 3.4%

Kent Lake Capital LLC 2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
ORBIMED ADVISORS LLC	13F Company 13F	12%	$41,280,900 4,003,967 shares	—	31 Dec 2023
MORGAN STANLEY	13F Company 13F	7.2%	$25,369,982 2,460,716 shares	—	31 Dec 2023
Soleus Capital Management, L.P.	13F Company 13F	7.1%	$25,085,962 2,433,168 shares	—	31 Dec 2023
Nantahala Capital Management, LLC	13F Company 13F	3.4%	$12,100,610 1,173,677 shares	—	31 Dec 2023
Kent Lake Capital LLC	13F Company 13F	2%	$6,917,453 670,946 shares	—	31 Dec 2023
FMR LLC	13F Company 13F	1.4%	$4,825,915 468,081 shares	—	31 Dec 2023

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

13,364,973

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q1 2024 Across Filers

Q1 2024 holders

Holder diff

Investor	Q1 2024 Shares	Q1 2024 Shares	Share Diff	Share Chg %	Q1 2024 value	Q1 2024 value	Value change	Value Chg %